Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-30T20:14:51.002Z Has data issue: false hasContentIssue false
  • English
  • Français

The spectrum of subjective effects of antipsychotic medication

Published online by Cambridge University Press:  24 June 2014

Hugo A Wolters ,
Rikus Knegtering ,
Durk Wiersma  and
Robert J van den Bosch
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

This study examined the spectrum of subjective experiences which patients attribute to the use of antipsychotic medication.

Methods:

We collected interview data and answers to structured questions based on a comprehensive checklist in 77 patients using various types of classical or atypical antipsychotic drugs.

Results:

The responses of the patients could be categorized into psychological and somatic domains. The psychological domain could be subdivided into emotional, cognitive and sociability domains. The somatic set could be subdivided into activation and physiological domains.

Conclusions:

Our data reveal that the same effects may be experienced in either a positive or a negative way by different patients. We conclude that existing scales for measuring subjective effects of antipsychotic medication are incomplete.

Keywords

subjectiveantipsychoticsside-effectsschizophrenia
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 15 , Issue 5 , October 2003 , pp. 274 - 279
Copyright
Copyright © 2003 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Van Putten, T, May, PR, Marder, SR, Wittmann, LA. Subjective response to antipsychotic drugs. Arch General Psychiatry 1981;38: 187–190. CrossRefGoogle ScholarPubMed
Weiden, PJ, Mann, JJ, Dixon, L, Haas, G, Dechillo, N, Frances, AJ. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989;30: 546–552.CrossRefGoogle ScholarPubMed
Naber, D, Walther, A, Kircher, T, Hayek, D, Holzbach, R. Subjective effects of neuroleptics predict compliance. In: Gaebel, WAwad, AG, eds. Predictions of Neuroleptic Treatment Outcome in Schizophrenia. Wien: Springer Verlag, 1994: 85–98. CrossRefGoogle Scholar
Agarwal, MR, Sharma, VK, Kishore-Kumar, KV, Lowe, D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44: 92–106.CrossRefGoogle ScholarPubMed
Cabeza, GI, Amador, SM, Lopez, AC, De Chavez, CM. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000;41: 349–355.CrossRefGoogle ScholarPubMed
Van Putten, T, May, PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch General Psychiatry 1978;35: 477–480. CrossRefGoogle ScholarPubMed
Hogan, TP, Awad, AG, Eastwood, MR. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985;30: 246–248.CrossRefGoogle Scholar
Hogan, TP, Awad, AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22: 347–352.CrossRefGoogle ScholarPubMed
Naber, D. Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int Clin Psychopharmacol 1998;13: S41–S45. CrossRefGoogle Scholar
Van Putten, T. Why do schizophrenic patients refuse to take their drugs? Arch General Psychiatry 1974;31: 67–72. CrossRefGoogle ScholarPubMed
Awad, AG, Hogan, TP, Voruganti, LN P, Heslegrave, RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl. 3):123–132.Google ScholarPubMed
Awad, AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19: 609–618.CrossRefGoogle Scholar
Naber, D. A self-rating scale to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10(Suppl. 3):133–138.Google ScholarPubMed
Naber, D, Moritz, S, Lambert, Met al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic medication. Schizophr Res 2001;50: 79–88.CrossRefGoogle Scholar
Diamond, R. Drugs and the Quality of Life: The Patient's Point of View. J Clin Psychiatry 1985;46: 29–35.Google ScholarPubMed
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, S, Elgen, K. The UKU side effect scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;34(Suppl. 76): 1–100. CrossRefGoogle Scholar
Hogan, TP, Awad, AG, Eastwood, MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13: 177–183.CrossRefGoogle ScholarPubMed